← Eichor
Study identifier: NCT05789043 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

Condition: Acral Melanoma  ·  Sponsor: Peking University Cancer Hospital & Institute

PhasePhase 3
Planned participants140
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

It is a RCT aimed to evaluate the Progression Free Survival of Camrelizumab combined with apatinib and temozolomide as First Line Therapy in Advanced Acral Melanoma.

This description comes directly from the study's public registry record.

Talk to the study team

Jun Guo, Dr  ·  010-88121122  ·  guoj307@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing Cancer HospitalBeijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05789043